We use cookies to understand how you use our site and to improve your experience. Please refer to our Terms and Conditions and Privacy Policy for more information about the cookies we use and how we protect your privacy.
A frequent complication after transplantation, Cytomegalovirus (CMV) infection may cause a series of direct and indirect effects that lead to increased incidence of graft rejection, opportunistic infections, and decreased allograft and patient survival.1,2
How does Viracor help you fight CMV?
1. Early Detection of CMV Reactivation, Primary Infections
2. Monitor Response to Treatment
3. Confirm Antiviral Resistance
4. Establish Immunity
What are the benefits of working with us?
- Industry leading turnaround time for all of our CMV Assays
- Constant assay refinement with the use of dual targets, multiple probes and mutation surveillance means you know your patient will be evaluated using the most up-to-date and accurate testing
- Ability to send all of your CMV testing to one lab – offering 3 unique assays in one location to assist with the CMV continuum of care for your immunocompromised patients:
- PCR viral load for adults and neonates
- Drug Resistance, including the newest FDA-approved drug, Prevymis™ (letermovir).
- T Cell Immunity, which uniquely evaluates CD4 and CD8 T cells
- Multiple specimen types accepted for ease of collection
Watch how Viracor's CMV T Cell Immunity Panel Helps A Post-Transplant CMV Treatment Plan
Understand how your patient's immune system is responding to CMV medication.
Optimizing CMV Outcomes
Viracor can make it easier for healthcare providers to manage CMV patients with testing options spanning the continuum of care.
Baseline & Monitor Viral Load
Quantitative CMV PCR can be used for early detection of reactivation, primary infection and monitoring response to treatment.
Dual gene targets and multiple probes increases the assay’s ability to pick up polymorphisms, therefore reducing the chance for false negatives and detecting other strains that could otherwise be missed.
Confirm Antiviral Resistance
Patient outcomes depend on effective prophylaxis and treatment with antiviral therapies, including ganciclovir, valganciclovir, foscarnet, cidofovir and letermovir.
Laboratory testing should be used to confirm drug resistance, as treatment modification based solely on clinical suspicion may result in added toxicity and increased complexity in patient management.
Establish Immunity
The CMV T Cell Immunity Panel measures the strength of T cell responses to CMV-specific antigens and reports the activity of CD4 and CD8 T cell responses independently.
Evaluating immunocompromised patients’ CMV-specific T cell response will help healthcare providers decide when to take patients off of antiviral medication during critical stages in treatment.
BMC Infectious Diseases
NEW RESEARCH ARTICLE:
Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events
Published CMV Data from Viracor's Scientific Team
Send your CMV testing to a lab that's leading the industry in CMV testing research and development. Read how Viracor is taking CMV clinical diagnostic testing to the next level.
Viracor's CMV Testing for Transplant & Immunocompromised Patients
| Test Name | Test Code | Turnaround Time & Test Details | ||
| PCR / Viral Load |
CMV Real-time Quantitative PCR |
5500 |
|
|
| CMV Saliva Real-time PCR |
5571 |
|
||
|
Resistance |
CMV Resistance: Letermovir, Ganciclovir, Foscarnet, Cidofovir |
30721 |
|
|
|
5600 |
||||
|
30722 |
||||
| Immunity | CMV T Cell Immunity Panel | 30360 |
|
|
WE KNOW CMV.
Learn how we can help your hospital or lab streamline your CMV sample collection, turnaround time and testing results.
CAP Accredited. CLIA Licensed. NY State Certified.
EMAIL USReferences
1 Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. Apr 15 2010;89(7):779-95.
2 Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711-9.
Connect with us